OVERVIEW OF THE DREAMM-2 STUDY

PURPOSE — **EVALUATION OF THE SAFETY AND EFFICACY OF BLENREP**

Inclusion Criteria

Eligible patients were required to:
- have relapsed or refractory multiple myeloma
- have previously received ≥3 prior therapies (including an anti-CD38 monoclonal antibody)
- be refractory to an immunomodulatory agent and a proteasome inhibitor
- have measurable disease according to IMWG criteria

(Not an all inclusive list. See ClinicalTrials.gov Identifier: NCT03525678)

Design

- Open-label, multicenter
- Two treatment groups received Blenrep until disease progression or unacceptable toxicity
  - 2.5 mg/kg intravenously once every 3 weeks (recommended dosage) OR
  - 3.4 mg/kg intravenously once every 3 weeks (1.4x the recommended dose)

Efficacy Outcome Measure

Overall response rate based on the IMWG Uniform Response Criteria for Multiple Myeloma

Exclusion Criteria

Patients were excluded from the study if they had:
- corneal epithelial disease at baseline; exception: mild punctate keratopathy

(Not an all inclusive list. See ClinicalTrials.gov Identifier: NCT03525678)

Study Population

218 patients received Blenrep (safety population)



24% were exposed for ≥6 months

Baseline demographics of 2.5 mg/kg treatment group (n=97)

Median age: **65** years (range: 39-85)

53% male

74% White

16% Black

Median number of prior lines of therapy: **7** (range: 3-21)

77% were ISS Stage II or III

16% had an ECOG performance status of 2

87% received prior ASCT

27% had high-risk cytogenetic factors present

ASCT: Autologous Stem Cell Transplantation; ECOG: Eastern Cooperative Oncology Group; IMWG: International Myeloma Working Group; ISS: International Staging System